These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 6933259)

  • 21. [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus].
    Oltmanns D; Dennin DE; Pentz R; Siegers CP
    Z Gastroenterol; 1984 Oct; 22(10):598-601. PubMed ID: 6506825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition of antipyrine and phenytoin correlated with age and liver volume in man.
    Bach B; Hansen JM; Kampmann JP; Rasmussen SN; Skovsted L
    Clin Pharmacokinet; 1981; 6(5):389-96. PubMed ID: 7333060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipyrine kinetics following tetanus vaccination.
    Descotes J; Simonet R; Evreux JC
    Int J Clin Pharmacol Ther Toxicol; 1986 Nov; 24(11):625-6. PubMed ID: 3793297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased values of antipyrine clearance in type IV hyperlipoproteinemia.
    Bedeleanu D; Trif I; Lötsch JC; Cucuianu MP
    Med Interne; 1986; 24(3):183-90. PubMed ID: 3775212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic profile of antipyrine in young rhesus monkeys (Macaca mulatta) with protein energy malnutrition.
    Sharma B; Mehta S; Nain CK; Mathur VS
    Drug Nutr Interact; 1985; 3(2):93-8. PubMed ID: 3921335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antipyrine metabolism in lung cancer patients].
    Radzikowska E; Gaździk W; Rowińska-Zakrzewska E
    Pneumonol Alergol Pol; 1993; 61(9-10):496-502. PubMed ID: 8111326
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [In vivo activity of drug-metabolizing enzymes in various pathological conditions].
    Krakovskiĭ ME; Ashirmetov AKh
    Vopr Med Khim; 1985; 31(1):76-9. PubMed ID: 3984279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of diabetes mellitus on drug metabolism in man.
    Daintith H; Stevenson IH; O'Malley K
    Int J Clin Pharmacol Biopharm; 1976 Jan; 13(1):55-8. PubMed ID: 1248919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic drug metabolizing capacity of patients of cirrhosis before and after clinico-biochemical recovery.
    Chauhan CK; Nanivadekar SA; Billimoria FR
    Indian J Physiol Pharmacol; 1989; 33(1):63-6. PubMed ID: 2737749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of a non-steroid anti-inflammatory agent on the drug metabolizing activity of the human liver.
    Gachályi B; Vas A; Káldor A
    Int J Clin Pharmacol Ther Toxicol; 1984 Jul; 22(7):353-4. PubMed ID: 6469424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipyrine kinetics following influenza vaccination.
    Simonet R; Descotes J; Evreux JC
    Int J Clin Pharmacol Res; 1986; 6(3):231-3. PubMed ID: 3744625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum levels of sex hormone-binding globulin (SHBG) are not associated with lower levels of non-SHBG-bound testosterone in male newborns and healthy adult men.
    de Ronde W; van der Schouw YT; Pierik FH; Pols HA; Muller M; Grobbee DE; Gooren LJ; Weber RF; de Jong FH
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):498-503. PubMed ID: 15807883
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monthly variations in the clearance of antipyrine in the rat.
    Bélanger PM; Doré F; Labrecque G
    Res Commun Chem Pathol Pharmacol; 1984 Oct; 46(1):53-65. PubMed ID: 6505390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The relationship between antipyrine kinetics and the change in the seromucoid content of rat plasma under the influence of the immunomodulator levamisole].
    Kupchikov VV; Bender KI; Lutsevich AN; Gangnus VS
    Farmakol Toksikol; 1990; 53(5):55-8. PubMed ID: 2253753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liver failure and drug metabolism.
    Andreasen PB; Ranek L
    Scand J Gastroenterol; 1975; 10(3):293-7. PubMed ID: 1138332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of sulfamerazine and antipyrine in neonatal and young lambs.
    De Backer P; Belpaire FM; Bogaert MG; Debackere M
    Am J Vet Res; 1982 Oct; 43(10):1744-51. PubMed ID: 7149373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenazone as a marker of liver-metabolic function in patients with acute leukemia.
    Wiela-Hojenska A; Orzechowska-Juzwenko K; Usnarska-Zubkiewicz L; Kotlarek-Haus S; Hurkacz M
    Int J Clin Pharmacol Ther; 1999 May; 37(5):234-7. PubMed ID: 10363621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.